trending Market Intelligence /marketintelligence/en/news-insights/trending/9BITM_p5WMBIAt3Rarn5tA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

EMERAM Capital-backed Meona buys pharmacy software provider Dr. Heni

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Gauging Supply Chain Risk In Volatile Times

EMERAM Capital-backed Meona buys pharmacy software provider Dr. Heni

EMERAM Capital Partners GmbH-backed Meona GmbH purchased Dr. Heni SOFTWARE GmbH & Co. KG for an undisclosed amount.

Dr. Heni Software, through its software products ZENZY and A-Taxe, supports hospitals and pharmacies in the production and billing of medicines and cytostatics drugs, which are natural or synthetic substances that inhibit cell growth or cell division.

Meona has been a portfolio company of EMERAM since 2017. EMERAM is a private investment firm focused on medium-sized businesses in German-speaking countries in the sectors of consumer goods, retail, industrial goods, business services and healthcare.

Dr. Heni Software founder Josef Heni was advised by Dr. Heni und Partner Steuerberater Rechtsanwälte PartGmbB, while Meona was advised by Friedrich Graf von Westphalen. Tax advice was provided by Melzer und Kollegen.